pharma · H. Pylori Infection · COVID-19
Jiangsu Province Centers for Disease Control and Prevention
Jiangsu Province Centers drug portfolio — 5 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Portfolio lens on 5 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Jiangsu Province Centers drug portfolio — 5 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Antiinfectives for systemic use (J07) compound in Jiangsu Province Centers's portfolio. Mechanism: Biological vaccine - induces immune response.
Development asset linked to Jiangsu Province Centers in public FDA and regional records.
Development asset linked to Jiangsu Province Centers in public FDA and regional records.
Development asset linked to Jiangsu Province Centers in public FDA and regional records.
Development asset linked to Jiangsu Province Centers in public FDA and regional records.